Research Analysts Offer Predictions for CATX FY2024 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Investment analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a note issued to investors on Wednesday, February 5th. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings of ($0.90) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Cantor Fitzgerald also issued estimates for Perspective Therapeutics’ FY2025 earnings at ($1.09) EPS.

A number of other equities research analysts have also weighed in on the stock. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Friday, January 24th. Oppenheimer cut their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. UBS Group began coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Finally, Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $24.00 to $5.00 in a report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics currently has an average rating of “Buy” and a consensus target price of $15.14.

Perspective Therapeutics Trading Down 3.7 %

Shares of Perspective Therapeutics stock opened at $3.41 on Friday. Perspective Therapeutics has a 52-week low of $2.70 and a 52-week high of $19.05. The company has a 50 day moving average of $3.49 and a 200 day moving average of $9.26.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The business had revenue of $0.37 million during the quarter.

Insiders Place Their Bets

In other Perspective Therapeutics news, Director Heidi Henson acquired 25,975 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were bought at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the completion of the purchase, the director now owns 25,975 shares in the company, valued at $100,003.75. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Johan M. Spoor bought 8,000 shares of Perspective Therapeutics stock in a transaction dated Wednesday, December 4th. The stock was acquired at an average cost of $3.77 per share, with a total value of $30,160.00. Following the completion of the acquisition, the chief executive officer now directly owns 36,257 shares of the company’s stock, valued at approximately $136,688.89. The trade was a 28.31 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 67,570 shares of company stock valued at $256,789 over the last quarter. Company insiders own 3.52% of the company’s stock.

Institutional Trading of Perspective Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CATX. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics during the fourth quarter worth approximately $34,000. Bank of New York Mellon Corp grew its position in Perspective Therapeutics by 3.4% in the 4th quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company’s stock valued at $458,000 after buying an additional 4,693 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Perspective Therapeutics in the 4th quarter valued at $33,000. Nicholson Wealth Management Group LLC increased its stake in Perspective Therapeutics by 0.4% in the 4th quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock valued at $5,134,000 after buying an additional 7,000 shares during the period. Finally, WealthPlan Investment Management LLC lifted its stake in shares of Perspective Therapeutics by 18.2% in the 4th quarter. WealthPlan Investment Management LLC now owns 401,049 shares of the company’s stock worth $1,279,000 after acquiring an additional 61,757 shares during the period. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.